23.07.2015 22:00:44

Ossur Hf : Q2 Results 2015

Announcement from Össur hf. no: 27/2015

Highlights Q2 2015

  • Sales amounted to USD 127 million, corresponding to local currency growth of 8% and 7% organic growth.

  • Bracing and supports sales growth was 8% and 8% organic, both measured in local currency

  • Prosthetics sales growth was 10% and 7% organic, both measured in local currency.

  • Gross profit amounted to USD 80 million and 63% of sales, compared to USD 85 million and 64% of sales in Q2 2014.

  • EBITDA amounted to USD 27 million or 21% of sales. Adjusted EBITDA amounted to USD 28 million or 22% of sales, compared to USD 29 million or 22% of sales in Q2 2014. Adjusted EBITDA grew by 7% in local currency.

  • Net profit amounted to USD 16 million or 12% of sales, compared to USD 17 million or 13% of sales in Q22014.

  • USD strengthening has had a significant impact on reported sales and profits when comparing to prior year results. Negatively impacting sales by USD 13 million and EBITDA by USD 2 million.

  • Cash generated by operations amounted to USD 23 million or 18% of sales, compared to USD 24 million or 18% of sales in Q2 2014.

Financial Guidance for 2015

The financial guidance for the full year of 2015 is unchanged except for capital expenditures.

  •  Total sales growth LCY in the range of 4-6%.

  • Organic sales growth LCY in the range of 3-5%.

  • EBITDA margin in the range of 20-21% of sales.

  • Capital expenditures 3.5-4.5% of sales (previously 2.5-3.5%).

  • Effective tax rate around 26%.

Jón Sigurðsson, President & CEO, comments:

"The results of this quarter are good. Strong growth and good profitability despite adverse impact from currency fluctuations. Prosthetics continue to perform well in all of our major markets and sales growth in bracing and supports was excellent in the quarter, driven by very strong performance in EMEA. At our Capital Markets Day in Copenhagen in May we proudly announced breakthrough technology by demonstrating innovation that allows users of Össur Bionic devices to control movement of the device with their thoughts. Although the commercialization of this technology is out in the future, this technological breakthrough demonstrates our ability to innovate and commitment to advancing the technology in the Prosthetics field."

Conference Call

Össur will host a conference call on Friday 24th July 2015 at 10:00 CET/ 8:00 GMT/ 4:00 EDT.

To participate in the call please dial:
Europe: + 45 3544 5580, +44 (0) 203 364 5374 or +46 (0) 8 505 564 74 
The United States: + 1 855 753 2230 
Iceland: +354 800 7417


This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ossur hf via Globenewswire

HUG#1940981

Analysen zu Ossur hfmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Ossur hf 35,30 1,15% Ossur hf